Seven Fleet Capital Management LP reported 92 positions worth $600.72M for the quarter ended Jun 30, 2026, up 258.8% on the prior quarter. It opened 22 new positions, added to 42, trimmed 22 and exited 22. Its largest holding is CG Oncology, Inc. at 22.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | +1.81M | +2,389.8% | $128.63M | 22.31% |
| TNGX Tango Therapeutics, Inc. | +2.73M | +543.0% | $80.78M | 15.92% |
| RVMD Revolution Medicines, Inc. | +161.2K | +199.6% | $30.20M | 7.55% |
| PHVS Pharvaris N.V. | +601.8K | +348.4% | $20.81M | 4.46% |
| MIRM Mirum Pharmaceuticals, Inc. | +110.4K | – | $12.92M | 2.15% |
| ASMB Assembly Biosciences, Inc. | +377.0K | +671.5% | $10.36M | 1.98% |
| AVTX Avalo Therapeutics, Inc. | +556.9K | +260.5% | $10.29M | 2.37% |
| ELVN Enliven Therapeutics, Inc. | +201.4K | +122.8% | $10.22M | 3.09% |
| MANE Veradermics, Inc | +80.0K | – | $9.84M | 1.64% |
| ABVX Abivax S.A. | +68.3K | +158.6% | $9.10M | 2.47% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TYRA Tyra Biosciences, Inc. | -195.7K | -100.0% | $7.49M | Exited |
| AGIO Agios Pharmaceuticals, Inc. | -152.6K | -72.8% | $5.66M | 0.352% |
| PCVX Vaxcyte, Inc. | -78.7K | -72.5% | $4.69M | 0.296% |
| MLYS Mineralys Therapeutics, Inc. | -69.6K | -100.0% | $1.88M | Exited |
| IDYA IDEAYA Biosciences, Inc. | -48.4K | -56.1% | $1.80M | 0.235% |
| RLAY Relay Therapeutics, Inc. | -79.5K | -30.9% | $1.49M | 0.555% |
| SLN Silence Therapeutics plc | -96.7K | -61.7% | $1.06M | 0.11% |
| KRYS Krystal Biotech, Inc. | -2,542 | -58.9% | $944.79K | 0.11% |
| REPL Replimune Group, Inc. | -120.4K | -100.0% | $921.06K | Exited |
| MAZE Maze Therapeutics, Inc. | -30.7K | -100.0% | $916.60K | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. | +110.4K | $12.92M | 2.15% |
| MANE Veradermics, Inc | +80.0K | $9.84M | 1.64% |
| EDIT Editas Medicine, Inc. | +1.33M | $4.31M | 0.718% |
| STRO Sutro Biopharma, Inc. | +159.1K | $3.79M | 0.632% |
| SGMT Sagimet Biosciences Inc. | +403.5K | $3.12M | 0.519% |
| PRAX Praxis Precision Medicines, Inc. | +7,540 | $2.52M | 0.42% |
| RLMD Relmada Therapeutics, Inc. | +348.3K | $2.41M | 0.401% |
| XENE Xenon Pharmaceuticals Inc. | +33.3K | $2.08M | 0.347% |
| SNDX Syndax Pharmaceuticals Inc | +77.9K | $1.65M | 0.274% |
| ANL Adlai Nortye Group Ltd. | +113.2K | $1.30M | 0.217% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| TYRA Tyra Biosciences, Inc. | -195.7K | $7.49M | 4.48% |
| MLYS Mineralys Therapeutics, Inc. | -69.6K | $1.88M | 1.13% |
| REPL Replimune Group, Inc. | -120.4K | $921.06K | 0.55% |
| MAZE Maze Therapeutics, Inc. | -30.7K | $916.60K | 0.547% |
| CLYM Climb Bio, Inc. | -130.7K | $894.98K | 0.535% |
| CMPS COMPASS Pathways plc | -158.0K | $873.86K | 0.522% |
| DNLI Denali Therapeutics Inc. | -35.3K | $677.49K | 0.405% |
| UTHR UNITED THERAPEUTICS Corp | -1,128 | $668.88K | 0.399% |
| LLY ELI LILLY & Co | -720 | $662.23K | 0.396% |
| VSTM Verastem, Inc. | -123.4K | $654.02K | 0.391% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. | Healthcare | 1.89M | $134.02M | 22.31% | +1.81M | +2,389.8% | Added | 2.14% |
| 2 | TNGX Tango Therapeutics, Inc. | Healthcare | 3.23M | $95.66M | 15.92% | +2.73M | +543.0% | Added | 1.92% |
| 3 | RVMD Revolution Medicines, Inc. | Healthcare | 242.0K | $45.33M | 7.55% | +161.2K | +199.6% | Added | 0.11% |
| 4 | PHVS Pharvaris N.V. | Healthcare | 774.5K | $26.78M | 4.46% | +601.8K | +348.4% | Added | 1.31% |
| 5 | LQDA Liquidia Corp | Healthcare | 256.6K | $20.46M | 3.41% | +68.7K | +36.6% | Added | 0.29% |
| 6 | ELVN Enliven Therapeutics, Inc. | Healthcare | 365.4K | $18.54M | 3.09% | +201.4K | +122.8% | Added | 0.5% |
| 7 | ABVX Abivax S.A. | Healthcare | 111.3K | $14.84M | 2.47% | +68.3K | +158.6% | Added | 0.16% |
| 8 | AVTX Avalo Therapeutics, Inc. | Healthcare | 770.8K | $14.24M | 2.37% | +556.9K | +260.5% | Added | 1.46% |
| 9 | MIRM Mirum Pharmaceuticals, Inc. | Healthcare | 110.4K | $12.92M | 2.15% | +110.4K | – | New | 0.17% |
| 10 | ASMB Assembly Biosciences, Inc. | Healthcare | 433.1K | $11.90M | 1.98% | +377.0K | +671.5% | Added | 2.18% |
| 11 | IPSC Century Therapeutics, Inc. | Healthcare | 4.35M | $10.65M | 1.77% | +1.40M | +47.5% | Added | 2.11% |
| 12 | CYTK Cytokinetics Inc | Healthcare | 118.2K | $10.07M | 1.68% | +57.0K | +93.0% | Added | 0.09% |
| 13 | TSHA Taysha Gene Therapies, Inc. | Healthcare | 1.50M | $9.94M | 1.65% | +878.7K | +140.4% | Added | 0.41% |
| 14 | MANE Veradermics, Inc | Healthcare | 80.0K | $9.84M | 1.64% | +80.0K | – | New | 0.19% |
| 15 | AVBP ArriVent BioPharma, Inc. | Healthcare | 246.6K | $8.57M | 1.43% | +196.4K | +390.7% | Added | 0.51% |
Tip. Select a row to see that position’s full history at Seven Fleet Capital Management.
As of its Q2 2026 13F filing, Seven Fleet Capital Management LP’s five largest positions were CG Oncology, Inc. (CGON) at 22.3%, Tango Therapeutics, Inc. (TNGX) at 15.9%, Revolution Medicines, Inc. (RVMD) at 7.5%, Pharvaris N.V. (PHVS) at 4.5%, Liquidia Corp (LQDA) at 3.4% of the reported portfolio.
Seven Fleet Capital Management LP reported a 13F portfolio worth $600.72M across 92 positions for Q2 2026. That is up 258.8% from the previous quarter.
Its largest purchases by value were CG Oncology, Inc. ($128.63M), Tango Therapeutics, Inc. ($80.78M), Revolution Medicines, Inc. ($30.20M). It opened 22 new positions.
Its largest sales by value were Tyra Biosciences, Inc. ($7.49M), Agios Pharmaceuticals, Inc. ($5.66M), Vaxcyte, Inc. ($4.69M). It exited 22 positions entirely.
From the Form 13F-HR reports Seven Fleet Capital Management LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.